What is Earlens Corporation?
Earlens Corporation is a privately held medical technology firm dedicated to revolutionizing the hearing experience for individuals with hearing loss. Its flagship product, the Earlens® Contact Hearing Solution, recognized as a TIME Top 100 Invention of 2020, directly stimulates the auditory system. This advanced, nonsurgical device utilizes a small lens to vibrate the eardrum, mimicking the natural hearing process and delivering an exceptionally broad bandwidth for superior sound quality. The system received FDA clearance in 2019 for its second generation, signaling ongoing innovation in the audiology space.
How much funding has Earlens Corporation raised?
Earlens Corporation has raised a total of $221M across 9 funding rounds:
Private Equity
$4.6M
Series A
$4.6M
Unspecified
$500K
Debt
$6.2M
Series B
$40M
Debt
$45M
Debt
$2M
Debt
$45M
Series C
$73M
Private Equity (2010): $4.6M, investors not publicly disclosed
Series A (2010): $4.6M, investors not publicly disclosed
Unspecified (2011): $500K, investors not publicly disclosed
Debt (2013): $6.2M, investors not publicly disclosed
Series B (2014): $40M backed by New Enterprise Associates, Lightstone Ventures, and Aisling Capital
Debt (2017): $45M with participation from CRG LP
Debt (2020): $2M led by PPP
Debt (2022): $45M supported by CRG
Series C (2022): $73M featuring Vertex Healthcare, RK Mellon, Windham Venture Partners, Cochlear, and SightLine Partners
Key Investors in Earlens Corporation
CRG LP
CRG LP is a global investment firm specializing in credit and select equity investments across healthcare, focusing on life sciences and healthcare services. They provide flexible growth capital solutions to enhance healthcare innovation.
Vertex Healthcare
Vertex Healthcare operates within the Hospitals & Physicians Clinics industry, headquartered in Bellville, Texas, and focuses on healthcare services.
Windham Venture Partners
Windham Venture Partners is a New York City-based venture capital firm with a strong focus on healthcare, particularly medical technology and digital health, leveraging deep industry relationships.
What's next for Earlens Corporation?
The substantial enterprise-level funding and recent strategic investment position Earlens Corporation for significant expansion and market penetration. This capital infusion is likely to fuel further research and development, enhance manufacturing capabilities, and broaden the company's commercial reach. The company's focus on a direct-to-system activation approach suggests a strategy aimed at capturing a substantial share of the hearing aid market by offering a distinct technological advantage over traditional devices. Future growth will likely involve scaling operations to meet increasing demand and potentially exploring new therapeutic applications for their core technology.
See full Earlens Corporation company page
